The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.
Eligibility
Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Is in good health
* Has body mass index (BMI) 18.0 to 32.0 kg/m\^2
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
* History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* History of cancer (malignancy)
Primary outcome measure(s)
Part 1: Area Under the Concentration Time Curve From Time 0 to 4 Weeks (AUC0-4w) of MK-1406 — Predose and at designated timepoints up to 4 weeks postdose Blood samples will be collected at pre-specified timepoints to determine the AUC0-4w of MK-1406.
Part 1 and Part 2: Number of Participants Who Experience One or More Adverse Events (AEs) — Up to approximately 43 days postdose An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Part 1 and Part 2: Number of Participants Who Experience At Least One Solicited Injection-Site Reaction — Up to approximately 7 days postdose Solicited injection-site reactions include tenderness, pain, redness/erythema, and swelling. Participants will record injection site reactions using a paper diary. The number of participants with solicited injection-site reactions will be reported.
Part 1 and Part 2: Number of Participants Who Discontinue Study Due to an AE — Up to approximately 43 days postdose An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study due to an AE will be reported.
Trial sites (3)
Facility
City
Region
Status
Research Centers of America ( Hollywood ) ( Site 0008)
Hollywood
Florida
Recruiting
Hassman Research Institute Marlton Site ( Site 0001)
Marlton
New Jersey
Recruiting
Velocity Clinical Research, Cleveland ( Site 0005)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.